Global Clinical Trial Supply And Logistics Market by Service (Storage & Retention, Logistics & Distribution) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global clinical trial supply and logistics market was valued at USD 3.0 billion in 2020. It is projected to grow at 7.1% compound annual growth rate (CAGR), between 2021 and 2028. Market growth can be attributed to increasing R&D spending by pharmaceutical and biopharmaceutical companies and the growing number of global clinical trials. Technological advancements in supply chain management are also driving the market. New technologies in supply chain management are being adopted due to the increasing complexity of clinical studies and increased competition. Sponsors faced many challenges in the last year due to the Covid-19 pandemic, which presented logistical problems for the clinical trial market. The conventional supply chain has undergone significant changes due to the widespread adoption of remote trials. To manage logistical challenges of remote trials, direct-to-patient methods were used. Sponsors can reach a wider audience with decentralized trials. Although the pandemic has increased acceptance for such trials, there will be continued high demand long after Covid-19.

A host of logistical problems have arisen for clinical trials since Britain's exit from the European Union. These issues include customs and border management, VAT management and the requirement for suppliers and sites to obtain Exporter of Records Identification numbers (EORI). These complications are likely to affect companies that contract U.K.-based CDMOs. They will continue to use U.K.-based CDMOs for now due to specific Investigational Medicinal Product Dossier(IMPD) or Clinical Trial Authorizations (CTA), which require them to maintain the same manufacturing and packaging addresses. They must also handle VAT reclaims in Europe and releases of additional qualified person (QP). This is a time-consuming task that requires collaboration with other supply chain partners.

Clinical studies are becoming more complex and costly. Third-party service providers are being used by drug developers to obtain clinical study materials and deliver them directly to patients and investigators. The market would see strong growth if it relied on outsourcing for all logistics and supply tasks related to clinical trials. This includes transporting clinical trial materials, including investigational drugs, to clinical sites and patient homes.

As pharmaceutical companies seek to standardize and harmonize clinical supply chains, clinical supplies are increasingly important. Information silos can make planning more difficult and create unnecessary barriers and costs. Companies are experiencing a lack in visibility throughout the clinical supply chain, including actual inventory at clinics, outbound and inbound shipments, actual patients and dispensing schedules. There is also a lack in integration among many of the partners involved in the clinical supply chain industry.

The industry will need IT solutions that can adapt to the rapid growth of clinical studies. It is necessary to handle new umbrella, basket or platform trials, supply must be pooled and complex logistics and shelf life issues should be considered in clinical preparation. Future collaboration models will require different collaboration models, such as oboarding various clinical supply chain partners or IRT/RTMS vendors, cold-chain solution vendors (logistical services providers, contract manufacturers, etc.).

Service Insights

The market's largest segment, logistics and distribution, accounted for over 20% of the total revenue in 2020. This segment is expected to grow at the fastest rate during the forecast period. This is due to the globalization of clinical trials, an increase in the number of trials involving temperature-sensitive products, and the highly regulated structure of the industry.

Both the outbound and inbound sides of the global market are being positively impacted by technological developments. There will be an increase in Point of Care (POC), diagnostic tools that allow for more local analysis and less transfer of blood, tissue and urine to a central location for future examinations. The value of outbound shipping has increased significantly as a result of the increasing number of costly biologic drugs currently in development. These drugs can take as long as two years to make and are very difficult to reproduce.

Smart packaging solutions such as passive and active thermo-regulated products ensure that shipment temperatures remain within acceptable ranges during transport and storage. This protects the contents. SENTRY and other GPS enabled devices can track the shipment's location and condition and send SMS notifications about any deviations and excursions.

Phase Insights

In 2020, the highest revenue share was held by phase III with over 40.0%. This is due to an increase in patients who are enrolled in phase III trials. Phase III trials allow investigators to compare the safety and effectiveness of the new treatment with the standard of care. Phase III clinical trials typically involve large numbers of patients, usually at least several hundred.

The highest number of clinical trials in Phase II was in 2020, and this trend will continue due to increased investments by both industry and non-industry sponsors in R&D. Nice System's clinical trial logistics survey found that 60% of phase II trials were outsourced in 2017. This is the highest percentage of all phases of outsourced clinical trials. The increasing number of drugs in Phase II will increase logistics and supply chain complexity, which will lead to increased demand for efficient supply chain and logistics and contribute to the market's growth.

Therapeutic Area Insights

In 2020, the cardiovascular diseases segment accounted for more than 25% of all revenue. This is due to the increasing number of cardiovascular research studies, and the increased number of companies that are focusing on developing new drugs for the market. Healthcare systems around the world are working to reduce the incidence of cardiovascular diseases like strokes and heart attacks by developing new therapeutic and diagnostic approaches.

In 2020, the oncology segment accounted for the second largest share. The high incidence of cancer is the reason. Cancer was the second leading cause of death worldwide in 2018, accounting for one in six deaths. These factors are why many pharmaceutical companies invest in developing new cancer treatments.

End-user insights

The market was dominated by the pharmaceuticals sector, which accounted for more than 40.0% of the total market share in 2020. This is due to increased clinical trials conducted by pharmaceutical companies as well as R&D investments made by these companies. Market growth is also supported by the internationalization of clinical trials.

The fastest growing segment in the future is the biologicals, with 7.3% growth. This could be due to the rising demand for biological products such as gene therapy and cell therapies and growing investment in product development. The market boom was also influenced by the Covid-19 pandemic, which contributed to an increase in vaccine demand worldwide.

Regional Insights

North America dominated the global market in 2020 with a 35.0% share. The market is driven by a rise in clinical trials being conducted by pharmaceutical companies. ClinicalTrials.gov reports that the United States is the country with the most clinical trial operations each year. A significant market presence is also responsible for the regional growth.

The fastest growing region in the forecast period is Asia Pacific, which is expected to record a 7.8% rate of growth. Asia Pacific has a large and diverse patient population, lower recruitment costs, and favorable policies which make it attractive for clinical research. Researchers are shifting their focus away from countries such as Japan, Australia, South Korea and Singapore to emerging markets like Thailand and China.

Market Share Insights & Key Companies

Market players are undertaking a variety of strategic activities to strengthen their services, including new partnerships, collaborations and geographic expansion. Paraxel announced in July 2021 that it would open a new China-based clinical trial supplies depot to aid patients and clinical sites. China is still a major growth market for Parexel and clinical trials.

Besides, the players are playing an important role in the Covid-19 pandemic by providing direct-to-patient/direct-from-patient services. Marken provides services for clinical trials at home, including DTP delivery and the collection of biological samples. Direct-to-patient services by Marken allow drugs to be delivered directly to the patient, rather than to the site. The company uses both direct-to-patient and traditional supply chains. It has controlled room temperatures, freezers and refrigerators. Packaging materials are equipped with GPS and remote temperature monitoring devices. This allows for cold chain, ultracold, and ambient temperature shipping. The following are some of the most prominent players in global logistics and supply for clinical trials:

• Piramal Pharma Solutions

• UDG Healthcare

• DHL

• FedEx

• Movianto

• Packaging Coordinators Inc.

• Thermo Fisher Scientific (Patheon).

• Catalent, Inc.

• Parexel

• Almac Group

• Marken

Up Market Research published a new report titled “Clinical Trial Supply And Logistics Market research report which is segmented by Service (Storage & Retention, Logistics & Distribution), By Players/Companies FedEx, Piramal Pharma Solutions, Marken,  Movianto, Almac Group, DHL, Packaging Coordinators Inc, Parexel,  UDG Healthcare, Catalent Inc, Thermo Fisher Scientific (Patheon)”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Clinical Trial Supply And Logistics Market Report Segments:

The market is segmented by Service (Storage & Retention, Logistics & Distribution).

Clinical Trial Supply And Logistics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Clinical Trial Supply And Logistics Market

Overview of the regional outlook of the Clinical Trial Supply And Logistics Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Clinical Trial Supply And Logistics Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Clinical Trial Supply And Logistics Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Storage & Retention

                2. Logistics & Distribution

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Clinical Trial Supply And Logistics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Clinical Trial Supply And Logistics Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.